Search

Your search keyword '"VanDevanter, D.R."' showing total 44 results
Start Over Author "VanDevanter, D.R."
44 results on '"VanDevanter, D.R."'

3. Building global development strategies for cf therapeutics during a transitional cftr modulator era

Author

Mayer-Hamblett, N., van Koningsbruggen-Rietschel, S., Nichols, D.P., VanDevanter, D.R., Davies, J.C., Lee, T., Durmowicz, A.G., Ratjen, F., Konstan, M.W., Pearson, K., Bell, S.C., Clancy, J.P., Taylor-Cousar, J.L., De Boeck, K., Donaldson, S.H., Downey, D.G., Flume, P.A., Drevinek, P., Goss, C.H., Fajac, I., Magaret, A.S., Quon, B.S., Singleton, S.M., VanDalfsen, J.M., and Retsch-Bogart, G.Z.

Published
2020
Full Text
View/download PDF

7. Longitudinal bacterial prevalence in cystic fibrosis airways: Fact and artifact.

Author

VanDevanter, D.R., LiPuma, J.J., and Konstan, M.W.

Subjects
*CYSTIC fibrosis, *OPPORTUNISTIC infections, *BACTERIAL diseases, *MEDICAL registries, *COHORT analysis
Abstract

• CF airways are prone to opportunistic infections that can drive local inflammation. • Prevalence changes were studied from 2001-2019 for 7 CF bacterial opportunists. • Overall opportunist prevalence generally fell as population health improved. • Year-to-year prevalence change rates differed across organisms and birth cohorts. • More people changed infection status yearly than was suggested by prevalence change. Opportunistic bacterial infection is a hallmark of cystic fibrosis (CF) lung disease and early mortality. Poorly characterized prevalence changes have accompanied two decades of health improvements, with CFTR modulators likely to further affect infection epidemiology. Bacterial prevalence change trends across birth cohorts were assessed with linear regression using 2001–2019 US CF Foundation Patient Registry data. Informative missingness was assessed, as was age-to-age infection status. Bacterial prevalence constantly changed from 2001 to 2019, with changes differing across birth cohorts. Informative censoring affected prevalence change for some organisms. Age-to-age infection status changes were greater than net changes in bacterial prevalence and varied by age. CF infection epidemiology changed over two decades and will continue to do so. Understanding how modulators affect infection epidemiology will require creative designs for longitudinal prevalence change studies emphasizing prevalence changes independent of effects on lung biology. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

8. WS03.05 Multicenter validation of the cystic fibrosis-ABLE score as a predictor of outcome and therapeutic response in cystic fibrosis

Author

McElvaney, O.J., primary, Casey, M., additional, Meurling, I., additional, McCarthy, C., additional, Wade, P., additional, Connor, E.O’, additional, Pinto-Lee, J., additional, Bagwe, I., additional, Kaur, H., additional, Gringauze, M., additional, Fay, J., additional, Herron, M., additional, Gunaratnam, C., additional, VanDevanter, D.R., additional, Konstan, M.W., additional, Mayer-Hamblett, N., additional, Ramos, K.J., additional, Goss, C.H., additional, McKone, E.F., additional, and McElvaney, N.G., additional

Published
2023
Full Text
View/download PDF

19. Pure chromosome-specific PCR libraries from single sorted chromosomes

Author

VanDevanter, D.R., Choongkittaworn, N.M., Dyer, K.A., Aten, J., Otto, P., Behler, C., Bryant, E.M., and Rabinovitch, P.S.

Subjects
Polymerase chain reaction -- Research, Chromosomes -- Analysis, Science and technology
Abstract

A method based on either a chromosome fragment or an individual flow-sorted chromosome subjected to polymerase chain reaction (PCR) was used to produce chromosome-specific DNA sequences for chromosome-specific DNA libraries. This technique facilitated the production of probes and specific linkage maps, used to characterize solid tumor marker chromosomes. Chromosome-specific DNA libraries were used to study genome mapping in cytogenesis and molecular biology.

Published
1994

44. Design and powering of cystic fibrosis clinical trials using rate of FEV1 decline as an efficacy endpoint

Author

Konstan, M.W., Wagener, J.S., Yegin, A., Millar, S.J., Pasta, D.J., and VanDevanter, D.R.

Subjects
*CYSTIC fibrosis treatment, *PULMONARY function tests, *EPIDEMIOLOGY, *PSEUDOMONAS aeruginosa infections, *CLINICAL trials, *MEDICAL care, *UNCERTAINTY (Information theory)
Abstract

Abstract: Background: Rate of lung function decline (RLFD) (as FEV1 percent predicted/yr) is a robust measure of CF therapeutic efficacy rarely used as a study endpoint, in part due to uncertainty of sample size requirements. Methods: Sample size requirements for 1:1 randomizations to detect RLFD treatment effects from 20% to 80% were assessed in Epidemiologic Study of CF (ESCF) patients. Effects of measuring FEV1 1–4 times per year in studies of 1- to 4-year durations were assessed in 399 patients age ≥6years with FEV1 ≥70%. Impacts of inclusion/exclusion based on risk factors in 2369 ESCF patients were assessed over 1.5years using semi-annual FEV1 measures. Results: Increasing study duration and exclusion of lower risk patients (e.g., no P. aeruginosa infection) both substantially reduced requirements. Conclusions: CF RLFD studies of 1.5years in duration appear feasible provided that investigators account for the beneficial effects of subject inclusion/exclusion based on risk factors in power estimates. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results